A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 579 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR 10 Ways You Can Nurture A More Sustainable Garden June 18, 2021 Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... October 30, 2019 Apple Season is Here! October 1, 2021 Study Says Educational Materials for Chemo Often Require Higher Reading Level... September 25, 2019 Load more HOT NEWS New on NCI’s Websites for March 2021 Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain Young Tulsa Mom Grows Closer To Her Own Mom During Almost... Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with...
